Karyopharm Therapeutics Inc. (KPTI) is poised for a pivotal year, with key catalysts ahead that could redefine the standard of care in myelofibrosis and bring meaningful advances to patients.
Myelofibrosis is a rare type of bone marrow cancer marked by extensive scarring in the bone marrow, leading to severe anemia, fatigue, splenomegaly, constitutional symptoms, and poor overall survival. While JAK inhibitors like Ruxolitinib (sold under the brand names Jakafi and Jakavi), Fedratinib, Pacritinib, and Momelotinib remain the current standard of care for myelofibrosis, their limitations - particularly in efficacy and durability - underscore the urgent need for more effective and disease-modifying therapies.
For comments and feedback: editorial@rttnews.com